Skip to content
STAT: psychedelics· Elaine Chen·PickAI score78

Definium says LSD therapy DT120 eased anxiety in second late-stage trial

STAT+: Definium’s LSD therapy eased anxiety in second large trial

AI summary

Definium Therapeutics said its LSD therapy DT120 helped patients with anxiety in a second late-stage trial。

Why it matters

The reported 5.1-point gap between DT120 and placebo mirrors the company's first late-stage anxiety study, so the pending regulatory filing will test whether that effect size holds up in a review.

Key facts

Kind of item
Trial results
Compound
LSD
Condition
Anxiety
Source
STAT: psychedelics (statnews.com)
Published
How this summary was made

The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: STAT: psychedelics · statnews.com

Connected to

Kind of item
Trial results
Compound
LSD
Condition
Anxiety

Other recent items on these topics